中国人群暴露后预防接种人用狂犬病疫苗的安全性与免疫原性:系统综述与Meta分析
该研究系统检索PubMed、EMBASE、CNKI和Cochrane Library数据库,纳入32项研究进行Meta分析,评估中国人群暴露后预防(PEP)接种狂犬病疫苗的安全性与免疫原性。结果显示PEP接种后可诱导机体产生足够的狂犬病病毒中和抗体(RVNA),Essen方案与Zagreb方案均显示良好免疫原性,两者全身和局部不良事件无显著差异,但Zagreb方案下局部和全身事件发生率相对较高。结论认为对中国人群PEP接种狂犬病疫苗具有良好的免疫效果和可接受的安全性,Zagreb方案与Essen方案在狂犬病预防方面相当且安全性可接受。
要点
- PEP接种狂犬病疫苗后可诱导机体产生足够的狂犬病病毒中和抗体(RVNA)。
- Essen方案与Zagreb方案均显示良好免疫原性,两者全身和局部不良事件无显著差异。
- Zagreb方案下局部和全身事件发生率相对较高,但安全性仍可接受。
核心结论
- 对中国人群,PEP接种狂犬病疫苗显示出较好的免疫效果和可接受的安全性,用于预防人狂犬病。
- Zagreb方案与Essen方案在狂犬病预防方面相当,且安全性可接受。
研究设计与样本
- 系统检索PubMed、EMBASE、CNKI和Cochrane Library数据库并辅以手工检索,由两名评价员独立筛选文献、提取数据和质量评价后,使用Stata 16.0软件进行Meta分析,共纳入32项研究。
主要发现
- PEP接种狂犬病疫苗后可诱导机体产生足够的RVNA。
- Essen方案与Zagreb方案均显示良好免疫原性,PEP后全身事件和局部事件无显著差异。
- Zagreb方案下PEP后局部和全身事件发生率相对较高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate the safety and immunogenicity of rabies vaccine for human use after post-exposure in China. METHODS: A systematic search was performed from PubMed, EMBASE, CNKI and Cochrane Library database, supplemented by manual retrieval. According to the inclusion and exclusion criteria, a meta-analysis was performed using Stata 16.0 software after independent literature screening, data extraction and quality assessment by two evaluators. RESULTS: A total of 32 studies were included. It was found that rabies vaccination after PEP could induce the body to produce sufficient RVNA. Both Essen and Zagreb regimens showed good immunogenicity, with no significant difference in systemic events and local events after PEP, but a relatively high incidence of local and systemic events after PEP under the Zagreb regimen. CONCLUSION: For the Chinese population, rabies vaccination after PEP has shown relatively a good immune efficacy and acceptable safety for preventing human rabies. The survey also found that the Zagreb regimen was comparable to the Essen regimen in terms of rabies prophylaxis with an acceptable safety profile.
引用
- Wang L, Zhang J, Meng S, et al. Safety and immunogenicity of human rabies vaccine for the Chinese population after PEP: A systematic review and meta-analysis. Vaccine. 2022. PMID: 35750539. doi:10.1016/j.vaccine.2022.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。